- Home
- PACB vs QURE Comparison
PACB vs QURE Comparison
Compare PACB & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PACB
- QURE
- Stock Information
- Founded
- PACB 2000
- QURE 1998
- Country
- PACB United States
- QURE Netherlands
- Employees
- PACB N/A
- QURE N/A
- Industry
- PACB Biotechnology: Laboratory Analytical Instruments
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- PACB Industrials
- QURE Health Care
- Exchange
- PACB Nasdaq
- QURE Nasdaq
- Market Cap
- PACB 452.1M
- QURE 432.6M
- IPO Year
- PACB 2010
- QURE 2007
- Fundamental
- Price
- PACB $2.42
- QURE $7.33
- Analyst Decision
- PACB Buy
- QURE Buy
- Analyst Count
- PACB 15
- QURE 6
- Target Price
- PACB $3.79
- QURE $17.00
- AVG Volume (30 Days)
- PACB 9.3M
- QURE 699.6K
- Earning Date
- PACB 11-07-2024
- QURE 11-05-2024
- Dividend Yield
- PACB N/A
- QURE N/A
- EPS Growth
- PACB N/A
- QURE N/A
- EPS
- PACB N/A
- QURE N/A
- Revenue
- PACB $188,871,000.00
- QURE $28,587,000.00
- Revenue This Year
- PACB N/A
- QURE $178.43
- Revenue Next Year
- PACB $27.48
- QURE $49.15
- P/E Ratio
- PACB N/A
- QURE N/A
- Revenue Growth
- PACB 29.24
- QURE N/A
- 52 Week Low
- PACB $1.16
- QURE $3.73
- 52 Week High
- PACB $10.65
- QURE $11.35
- Technical
- Relative Strength Index (RSI)
- PACB 73.20
- QURE 61.28
- Support Level
- PACB $2.38
- QURE $5.35
- Resistance Level
- PACB $2.40
- QURE $7.28
- Average True Range (ATR)
- PACB 0.20
- QURE 0.50
- MACD
- PACB 0.07
- QURE 0.04
- Stochastic Oscillator
- PACB 89.31
- QURE 85.75
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.